Participated · Series B · Oct 2025

Cartography Biosciences develops antibody-based cancer therapies by integrating large-scale single-cell datasets with computational biology through its ATLAS and SUMMIT discovery platforms. The company aggregates petabyte-scale proprietary data from healthy tissues and tumor profiles and applies machine learning and AI to identify tumor-restricted antigens and antigen combinations. Its platform supports the design of logic-gated and highly selective antibody therapeutics aimed at improving specificity and therapeutic index. Cartography is advancing a pipeline of oncology programs with its lead candidate, CBI-1214, a T-cell engager for colorectal cancer that entered clinical testing in early 2026 and is currently enrolling patients in a Phase 1 trial. The company stated that the strategic investment from Samsung Ventures will help accelerate its oncology programs and expand its drug discovery capabilities.

Participated · Series B · Dec 2024

Nuvig Therapeutics is a clinical-stage biotechnology company developing novel immunomodulatory therapeutics to reduce autoimmune dysregulation without broad immunosuppression. Its lead candidate, NVG-2089, is a first-in-class recombinant Fc fragment engineered to bind type II Fc receptors and engage an endogenous regulatory mechanism that improves autoimmune dysregulation. Phase 1 single ascending dose and multiple ascending dose studies of NVG-2089 have been completed and showed safety, tolerability, dose-proportional pharmacokinetics, and pharmacodynamic evidence of target engagement. The company is advancing NVG-2089 into Phase 2 development in chronic inflammatory demyelinating polyneuropathy (CIDP) and other undisclosed indications with high unmet need. Proceeds from the Series B financing will support clinical proof-of-concept studies for NVG-2089 and advance Nuvig's preclinical pipeline. Nuvig is based in Menlo Park, California. Nuvig is developing genetically engineered protein therapeutics that activate immune-regulatory receptors to re-establish immune homeostasis following inflammation. The company is building a pipeline of differentiated protein candidates designed to target affected tissues in a disease-specific manner. Nuvig’s approach aims to rebalance immune function rather than rely on traditional immune suppression, with a lead molecule the company believes could offer a differentiated safety and efficacy profile. Management states initial preclinical data support broad activity across a variety of autoimmune diseases. The company plans a clinical development strategy to quickly obtain proof-of-concept in patients, followed by indication expansion and further pipeline growth. To support these plans, Nuvig has secured external financing to advance its programs toward the clinic.